齐拉西酮与阿立哌唑治疗60例精神分裂症的疗效和不良反应分析

Evaluation of Ziprasidone and Aripiprazole for schizophrenia and adverse reactions

目的:评价齐拉西酮与阿立哌唑对精神分裂症治疗的疗效和不良反应。方法:将60例住院精神分裂症患者随机分为两组,分别给予齐拉西酮和阿立哌唑治疗,疗程8周。在治疗前及治疗1、2、4、6、8周末分别采用阳性与阴性症状量表(PANSS)和副反应量表(TESS)评定疗效及不良反应。结果:两药对精神分裂症疗效相当:两组PNASS评分治疗后较治疗前均有显著下降,两组间差异无显著性;两组总不良反应发生率差异无显著性,但表现有异同。结论:齐拉西酮和阿立哌唑对精神分裂症均有较好的疗效,且不良反应小。

Objective：To evaluate Ziprasidone and Aripiprazole for schizophrenia and adverse reactions. Methods ：60 hospitalized patients with schizophrenia were randomly divided into two groups, were given Ziprasidone and Aripiprazole treatment, treatment for 8 weeks. Before treatment and treatment over the weekend 1,2,4,6,8 respectively positive and negative symptom scale （PANSS） and side reaction scale （TESS） assessed the efficacy and adverse reactions. Results： The two drugs for schizophrenia rather： PNASS score two more before treatment after treatment were significantly decreased, between the two groups there was no significant difference ; two sets of the total incidence of adverse reactions there was no significant difference, however, there are similarities and differences between the performance of. Conclusions： Ziprasidone and Aripiprazole for schizophrenia have better efficacy, adverse reactions is small.